Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Multicenter, Non-randomized, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BM230 in Patients With Advanced Solid Tumors

NCT06644300 is registered in ClinicalTrials.gov with Suzhou Biomissile Pharmaceuticals Co., Ltd. as lead sponsor.

NCT NCT06644300
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06644300 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Multicenter, Non-randomized, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BM230 in Patients With Advanced Solid Tumors
Lead sponsor
Suzhou Biomissile Pharmaceuticals Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
December 16, 2024
Completion date
December 31, 2027
Enrollment
123 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor